Bicara Therapeutics Announces Closing of Oversubscribed Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

Rhea-AI Summary

Bicara Therapeutics (Nasdaq: BCAX) closed an oversubscribed underwritten public offering on Feb 26, 2026, selling 8,581,250 shares and offering pre-funded warrants for 2,200,000 shares.

The underwriters fully exercised a 1,406,250-share option. Public prices were $16.00 per share and $15.9999 per pre-funded warrant, generating approximately $172.5 million gross proceeds before fees. Bicara plans to use net proceeds for regulatory filing and potential U.S. commercial launch of ficerafusp alfa, development in 1L R/M HPV-negative HNSCC, manufacturing, indication expansion signal-finding, and general corporate purposes.

Positive

• Raised approximately $172.5M gross proceeds
• Underwriters' option exercised in full, indicating strong demand
• Proceeds earmarked for regulatory filing and commercial launch funding

Negative

• Issuance of 8.58M shares plus 2.2M pre-funded warrants causes dilution
• Gross proceeds subject to underwriting discounts and offering expenses

News Market Reaction – BCAX

-0.12%

5 alerts

-0.12% News Effect

-$1M Valuation Impact

$920M Market Cap

0.1x Rel. Volume

On the day this news was published, BCAX declined 0.12%, reflecting a mild negative market reaction. Our momentum scanner triggered 5 alerts that day, indicating moderate trading interest and price volatility. This price movement removed approximately $1M from the company's valuation, bringing the market cap to $920M at that time.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

Common shares offered: 8,581,250 shares Pre-funded warrants: 2,200,000 warrants Warrant exercise price: $0.0001 per share +5 more

8 metrics

Common shares offered 8,581,250 shares Underwritten public offering

Pre-funded warrants 2,200,000 warrants Pre-funded warrants to purchase common stock

Warrant exercise price $0.0001 per share Exercise price of pre-funded warrants

Underwriters’ option shares 1,406,250 shares Additional shares via fully exercised option

Offering price (shares) $16.00 per share Public offering price of common stock

Offering price (warrants) $15.9999 per warrant Public offering price of pre-funded warrants

Gross proceeds $172.5 million Aggregate gross proceeds before fees and expenses

Share price pre-news $17.51 Price with +7.82% move before closing announcement

Market Reality Check

Price: $17.59 Vol: Volume 1,691,547 is about...

high vol

$17.59 Last Close

Volume Volume 1,691,547 is about 3.7x the 20-day average of 456,869, indicating heavy trading into the offering close. high

Technical Shares trade above the 200-day MA of $14.04, keeping BCAX in a pre-news uptrend despite the equity raise.

Peers on Argus

BCAX gained 7.82% while only one tracked peer (TYRA) appeared in momentum scanne...

1 Up

BCAX gained 7.82% while only one tracked peer (TYRA) appeared in momentum scanners with a modest move up, and others showed mixed, smaller changes. This points to a BCAX-specific reaction to the offering news rather than a broad biotech move.

Previous Offering Reports

2 past events · Latest: Feb 24 (Positive)

Same Type Pattern 2 events

Date	Event	Sentiment	Move	Catalyst
Feb 24	Offering priced	Positive	+7.8%	Priced $150M offering of common stock and pre-funded warrants.
Feb 24	Offering proposed	Positive	+7.8%	Commenced proposed $150M underwritten common stock offering.

Pattern Detected

Recent offering-related headlines have been followed by positive price reactions, suggesting equity raises tied to ficerafusp alfa development have been received constructively.

Recent Company History

Over February 2026, BCAX combined strong clinical updates for ficerafusp alfa with accelerated capital-raising activity. Two prior offering-tagged announcements on Feb 24, 2026 outlined a proposed and then priced $150M public offering, each followed by a 7.82% gain. Earlier in the month, positive Phase 1b data and additional investor-relations activities supported the development narrative. Today’s closing of the oversubscribed offering continues this sequence by finalizing the previously announced financing tied to regulatory and commercial plans.

Historical Comparison

+7.8% avg move · In recent BCAX history, two prior offering headlines averaged a 7.82% move, so the strong reaction a...

offering

+7.8%

Average Historical Move offering

In recent BCAX history, two prior offering headlines averaged a 7.82% move, so the strong reaction around this oversubscribed offering close is consistent with past capital-raise responses.

The company moved from proposing and pricing a $150M equity raise to closing an oversubscribed transaction, all tied to funding ficerafusp alfa’s regulatory and commercial path.

Regulatory & Risk Context

Active S-3 Shelf

Shelf Active

Active S-3 Shelf Registration 2025-10-03

BCAX has an active Form S-3 shelf filed on Oct 3, 2025, with multiple 424B5 takedowns recorded, including those linked to this offering. The shelf facilitates future registered securities offerings as needed, subject to its terms and expiration on Oct 3, 2028.

Market Pulse Summary

This announcement finalizes an oversubscribed equity financing, with BCAX selling 8,581,250 common s...

Analysis

This announcement finalizes an oversubscribed equity financing, with BCAX selling 8,581,250 common shares and 2,200,000 pre-funded warrants for gross proceeds of $172.5 million. The funds are earmarked to advance ficerafusp alfa toward a planned U.S. regulatory filing, commercial launch preparation, dosing-schedule optimization, manufacturing, and indication expansion work. Recent offering-related headlines have already outlined these priorities, so investors may focus next on clinical, regulatory, and execution milestones tied to this expanded capital base.

Key Terms

underwritten public offering, pre-funded warrants, shelf registration statement, form s-3, +1 more

5 terms

underwritten public offering financial

"announced the closing of its underwritten public offering of 8,581,250 shares"

An underwritten public offering is when a company sells new shares of its stock to the public with the help of a financial firm, called an underwriter. The underwriter agrees to buy all the shares upfront, reducing the company's risk, and then sells them to investors. This process helps companies raise money quickly and confidently from a wide range of buyers.

pre-funded warrants financial

"pre-funded warrants to purchase 2,200,000 shares of its common stock"

Pre-funded warrants are financial instruments that give investors the right to purchase a company's stock at a set price, but with most or all of the purchase price paid upfront. They function like a coupon or gift card for stock, allowing investors to buy shares later at a fixed price, which can be beneficial if they want to avoid future price increases. This makes them important for investors seeking flexibility and certainty in their investment plans.

shelf registration statement regulatory

"pursuant to an effective “shelf” registration statement on Form S-3"

A shelf registration statement is a document a company files with regulators that allows it to sell shares or bonds quickly when it’s a good time to raise money. It’s like having a pre-approved plan ready so the company can act fast without going through lengthy paperwork each time they want to sell, making fundraising more flexible.

form s-3 regulatory

"registration statement on Form S-3 (File No. 333-290707)"

Form S-3 is a legal document companies use to register their stock sales with the government, making it easier and faster for them to raise money by selling shares to investors. It’s like having a pre-approved shopping list that lets a company quickly sell new shares when they need funds, without going through a lengthy approval process each time.

prospectus supplement regulatory

"only by means of a prospectus supplement and an accompanying prospectus"

A prospectus supplement is an additional document provided alongside a company's main offering details, offering updated or extra information about a specific financial product being sold. It helps investors understand the latest terms, risks, and details of the investment, similar to how an update or revision clarifies or expands on original instructions, ensuring they have current and complete information before making a decision.

AI-generated analysis. Not financial advice.

BOSTON, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors, today announced the closing of its underwritten public offering of 8,581,250 shares of its common stock, and to certain investors that so choose, pre-funded warrants to purchase 2,200,000 shares of its common stock at an exercise price of $0.0001 per share. The shares of common stock sold include 1,406,250 shares pursuant to the option granted by Bicara to the underwriters, which option was exercised in full. The public offering price of each share of common stock was $16.00 and the public offering price of each pre-funded warrant was $15.9999. The aggregate gross proceeds to Bicara from this offering were approximately $172.5 million, before deducting underwriting discounts and commissions and other estimated offering expenses.

Bicara intends to use the net proceeds of the offering to further invest in and build its medical and commercial infrastructure to support a planned regulatory filing and commercial launch for ficerafusp alfa, if approved, in the U.S.; to further accelerate the development of ficerafusp alfa in 1L R/M HPV-negative HNSCC, including a less frequent dosing schedule; to fund manufacturing costs for ficerafusp alfa for ongoing and anticipated drug development efforts; to fund early signal-finding to support future indication expansion for ficerafusp alfa; and for other general corporate purposes.

Morgan Stanley, TD Cowen, BofA Securities, Cantor and Stifel acted as joint book-running managers for the offering.

The securities described above were offered by Bicara pursuant to an effective “shelf” registration statement on Form S-3 (File No. 333-290707) that was filed with the Securities and Exchange Commission (the “SEC”) on October 3, 2025 and declared effective on November 26, 2025. The securities was offered only by means of a prospectus supplement and an accompanying prospectus that form a part of the registration statement. A final prospectus supplement and the accompanying prospectus relating to and describing the offering have been filed with the SEC. Electronic copies of the final prospectus supplement and the accompanying prospectus relating to the offering may be obtained by visiting the SEC’s website at www.sec.gov or by contacting Morgan Stanley & Co. LLC, Attn: Prospectus Department, 180 Varick Street, 2^nd Floor, New York, NY 10014, or by email at prospectus@morganstanley.com; TD Securities (USA) LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717 or by email at TDManualrequest@broadridge.com; BofA Securities, NC1-022-02-25, 201 North Tryon Street, Charlotte, NC 28255-0001, Attention: Prospectus Department, or by email at dg.prospectus_requests@bofa.com; Cantor Fitzgerald & Co., Attention: Equity Capital Markets, 110 E. 59^th Street, 6^th Floor, New York, NY 10022, or by email at prospectus@cantor.com; or Stifel, Nicolaus & Company, Incorporated, Attention: Prospectus Department, One Montgomery Street, Suite 3700, San Francisco, CA 94104, by telephone at (415) 364-2720 or by email at syndprospectus@stifel.com.

This press release does not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of that state or jurisdiction.

About Bicara Therapeutics

Bicara Therapeutics is a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors. Bicara’s lead program, ficerafusp alfa, is a first-in-class bifunctional antibody designed to drive tumor penetration by breaking barriers in the tumor microenvironment that have challenged the treatment of multiple solid tumor cancers. Specifically, ficerafusp alfa combines two clinically validated targets: an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (“TGF-β”). Through this targeted mechanism, ficerafusp alfa reverses the fibrotic and immune-excluded tumor microenvironment driven by TGF-β signaling to enable tumor penetration that drives deep and durable responses. Ficerafusp alfa is being developed in head and neck squamous cell carcinoma, where there remains a significant unmet need, as well as other solid tumor types.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. These statements may be identified by words such as “may,” “might,” “will,” “could,” “would,” “should,” “plan,” “anticipate,” “intend,” “believe,” “expect,” “estimate,” “seek,” “predict,” “future,” “project,” “potential,” “continue,” “target” and similar words or expressions, or the negative thereof, are intended to identify forward-looking statements, although not all contain identifying words. Any statements in this press release that are not statements of historical fact may be deemed to be forward-looking statements. These forward-looking statements include, without limitation, the anticipated use of such proceeds from the offering. Any forward-looking statements in this press release are based on management's current expectations and beliefs and are subject to a number of risks and uncertainties that are difficult to predict. Factors that could cause actual results to differ include, but are not limited to, risks and uncertainties related to uncertainties inherent in the development of product candidates, including the conduct of research activities and the conduct of clinical trials; uncertainties as to the availability and timing of results and data from clinical trials; whether results from prior preclinical studies, preliminary or interim data from earlier stage clinical trials will be predictive of the results of subsequent preclinical studies and clinical trials; regulatory developments in the United States and foreign countries; whether Bicara’s cash resources will be sufficient to fund its foreseeable and unforeseeable operating expenses and capital expenditure requirements; as well as the risks and uncertainties identified in Bicara’s filings with the SEC, including its Annual Report on Form 10-K for the year ended December 31, 2024, its Quarterly Report on Form 10-Q for the quarter ended September 30, 2025 and any subsequent filings Bicara makes with the SEC. In addition, any forward-looking statements represent Bicara’s views only as of today and should not be relied upon as representing its views as of any subsequent date. Bicara explicitly disclaims any obligation to update any forward-looking statements. No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements.

Contacts:

Investors
Jenna Cohen
IR@bicara.com

Media
Amanda Lazaro
1AB
Amanda@1abmedia.com

FAQ

How much did Bicara (BCAX) raise in the Feb 26, 2026 public offering?

Bicara raised approximately $172.5 million in gross proceeds from the offering. According to the company, this total is before deducting underwriting discounts, commissions and estimated offering expenses, which will reduce net proceeds.

How many shares and pre-funded warrants did BCAX sell in the offering?

BCAX sold 8,581,250 shares and offered pre-funded warrants for 2,200,000 shares. According to the company, the underwriters also fully exercised a 1,406,250-share option.

What were the offering prices for Bicara (BCAX) shares and pre-funded warrants?

The public offering price was $16.00 per share and $15.9999 per pre-funded warrant. According to the company, those prices applied to the shares and the pre-funded warrants respectively.

What will Bicara (BCAX) use the offering proceeds for?

Proceeds will fund regulatory filing and potential U.S. commercial launch of ficerafusp alfa and related development. According to the company, funds will also support manufacturing, 1L R/M HPV-negative HNSCC development and indication expansion signal-finding.

Who managed the Bicara (BCAX) public offering that closed Feb 26, 2026?

Morgan Stanley, TD Cowen, BofA Securities, Cantor and Stifel acted as joint book-running managers. According to the company, these firms led the underwritten offering and handled prospectus distribution.

How does the pre-funded warrant exercise price affect BCAX shareholders?

Each pre-funded warrant has an exercise price of $0.0001, enabling immediate conversion with minimal cash when exercised. According to the company, this structure reduces cash burden for warrant holders but increases potential share dilution.